Acumen Pharmaceuticals, Inc.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Acumen Pharmaceuticals, Inc..The latest application filed is for "method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42".

Company Profile

0.10.12

Acumen Pharmaceuticals, Inc. - Livermore CA US
Acumen Pharmaceuticals, Inc. - Merck Sharp Dohme Corp.
Acumen Pharmaceuticals, Inc. - South San Francisco CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Grant 9,320,793 - Goure , et al. April 26, 2	2016-04-26
Antibodies, kit and method for detecting amyloid beta oligomers Grant 9,310,383 - Goure , et al. April 12, 2	2016-04-12
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production Grant 9,217,024 - Jerecic , et al. December 22, 2	2015-12-22
Method For Treating A Disease Associated With Soluble, Oligomeric Species Of Amyloid Beta 1-42 App 20150320860 - Goure; William F. ; et al.	2015-11-12
Antibodies, kit and method for detecting amyloid beta oligomers Grant 9,176,151 - Goure , et al. November 3, 2	2015-11-03
Antibodies, Kit And Method For Detecting Amyloid Beta Oligomers App 20150260731 - Goure; William F. ; et al.	2015-09-17
Methods of modifying amyloid .beta. oligomers using non-peptidic compounds Grant 9,006,283 - Krafft , et al. April 14, 2	2015-04-14
Methods of restoring cognitive ability using non-peptidic compounds Grant 8,962,677 - Krafft , et al. February 24, 2	2015-02-24
Monoclonal Antibodies That Target Pathological Assemblies Of Amyloid Beta (abeta) App 20130330837 - Lambert; Mary P. ; et al.	2013-12-12
Monoclonal antibodies that target pathological assemblies of amyloid .beta. (Abeta) Grant 8,507,206 - Lambert , et al. August 13, 2	2013-08-13
Method For Treating A Disease Associated With Soluble, Oligomeric Species Of Amyloid Beta 1-42 App 20130089537 - Goure; William F. ; et al.	2013-04-11
Amyloid Beta Peptides, Assemblies Thereof, And Related Methods App 20130078269 - Krafft; Grant A. ; et al.	2013-03-28
Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance Grant 7,964,359 - Zhao , et al. June 21, 2	2011-06-21
Methods Of Inhibiting The Formation Of Amyloid-beta Diffusable Ligands Using Acylhydrazide Compounds App 20110098309 - Look; Gary Charles ; et al.	2011-04-28
Novel Addl Receptor Polypeptides, Polynucleotides And Host Cells For Recombinant Production App 20100303897 - Jerecic; Jasna	2010-12-02
METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS App 20090018218 - Krafft; Grant A. ; et al.	2009-01-15
Methods Of Restoring Cognitive Ability Using Non-peptidic Compounds App 20090018084 - KRAFFT; Grant A. ; et al.	2009-01-15

Company Registrations

NCAGE Code	482E3	ACUMEN PHARMACEUTICALS, INC
CAGE Code	482E3	ACUMEN PHARMACEUTICALS, INC.
S.A.M. Registration	482E3 [155532190]	ACUMEN PHARMACEUTICALS, INC.
SEC	0001287184	ACUMEN PHARMACEUTICALS INC
SEC	0001576885	Acumen Pharmaceuticals, Inc. of DELAWARE

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.